Liquidia to Present at the Stifel 2024 Healthcare Conference
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, has announced its upcoming presentation at the Stifel 2024 Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 19, 2024, from 3:00 to 3:30 p.m. ET.
Investors and interested parties can access the live webcast through Liquidia's website investor section. A recorded version will remain available on the company's website for at least 30 days after the event.
Liquidia (NASDAQ: LQDA), un’azienda biofarmaceutica focalizzata sul trattamento di malattie cardiopolmonari rare, ha annunciato la sua prossima presentazione alla Conferenza Sanitaria Stifel 2024 a New York City. La presentazione è programmata per martedì 19 novembre 2024, dalle 15:00 alle 15:30 ET.
Investitori e parti interessate possono accedere alla diretta webcast tramite la sezione investitori del sito web di Liquidia. Una registrazione dell'evento sarà disponibile sul sito dell'azienda per almeno 30 giorni dopo l'evento.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica centrada en tratamientos para enfermedades cardiopulmonares raras, ha anunciado su próxima presentación en la Conferencia de Salud Stifel 2024 en la ciudad de Nueva York. La presentación está programada para el martes 19 de noviembre de 2024, de 3:00 a 3:30 p.m. ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Liquidia. Una versión grabada permanecerá disponible en el sitio de la empresa durante al menos 30 días después del evento.
Liquidia (NASDAQ: LQDA)는 희귀 심폐 질환 치료에 중점을 둔 생명공학 회사로, 뉴욕시에서 열리는 Stifel 2024 헬스케어 컨퍼런스에 대한 발표를 발표했습니다. 발표는 2024년 11월 19일 화요일 오후 3시부터 3시 30분(ET)으로 예정되어 있습니다.
투자자 및 관심 있는 분들은 Liquidia 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 녹화된 버전은 이벤트 후 최소 30일 동안 회사 웹사이트에서 제공됩니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur le traitement des maladies cardiopulmonaires rares, a annoncé sa prochaine présentation lors de la Conférence Santé Stifel 2024 à New York. La présentation est prévue pour le mardi 19 novembre 2024, de 15h00 à 15h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section investisseurs du site web de Liquidia. Une version enregistrée sera disponible sur le site de l'entreprise pendant au moins 30 jours après l'événement.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung seltener kardiopulmonaler Erkrankungen konzentriert, hat seine bevorstehende Präsentation auf der Stifel 2024 Healthcare Conference in New York City angekündigt. Die Präsentation ist für Dienstag, den 19. November 2024, von 15:00 bis 15:30 Uhr ET geplant.
Investoren und Interessierte können über den Investor-Bereich der Website von Liquidia auf den Live-Stream zugreifen. Eine aufgezeichnete Version wird für mindestens 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.
Access to the live webcasts will be available to investors and other interested parties via Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of each presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia (LQDA) presenting at the Stifel 2024 Healthcare Conference?
How can investors watch Liquidia's (LQDA) Stifel Conference presentation?
How long will Liquidia's (LQDA) Stifel Conference presentation recording be available?
What is the focus area of Liquidia (LQDA) as presented at the Stifel Conference?
